Yup, hard to argue that. Unlike other P&Ds, they actually have a product that sells and has a niche in the kidney care market.
At .07 a share, the dilution required to raise any reaonable amount of money would kill the share structure.....not to mention every time it pops, the selling gets ferocious and relentless.